| Literature DB >> 35721671 |
Charles Newton Odongo1, Carlos Cabrera Dreque2, David Mutiibwa2, Felix Bongomin3, Felix Oyania4, Mvuyo Maqhawe Sikhondze2, Moses Acan2, Raymond Atwine2, Fred Kirya1, Martin Situma2.
Abstract
Background: The diagnosis of extrahepatic obstructive jaundice (EHOJ) remains a challenge and is often made late in low-resource settings. Systematic data are limited on the etiology and prognosis of patients with obstructive jaundice in Uganda. The objective of this study was to determine the etiology, clinical presentations, and short-term treatment outcomes of patients managed for EHOJ at Mbarara Regional Referral Hospital (MRRH) in south-western Uganda.Entities:
Keywords: Uganda; benign obstructive jaundice; malignant obstructive jaundice
Year: 2022 PMID: 35721671 PMCID: PMC9199528 DOI: 10.2147/CEG.S356977
Source DB: PubMed Journal: Clin Exp Gastroenterol ISSN: 1178-7023
Descriptive Statistics for Basic Socio-Demographics of Participants
| Socio-Demographics (N = 72) | Variable | Frequency (%) |
|---|---|---|
| Age | <1 year | 7 (9.7) |
| 1–14 years | 3 (4. 2) | |
| 15–35 years | 4 (5.6) | |
| 36–50 years | 14 (19.4) | |
| >50 years | 44 (61.1) | |
| Gender | Male | 42 (58.3) |
| Female | 30 (41.7) | |
| History of smoking + alcohol intake | Alcohol consumption | 32 (44.4) |
| Smoking | 23 (32.0) | |
| Other chronic conditions | Human immunodeficiency virus | 8 (11.1) |
| Diabetes mellitus | 6 (8.3) | |
| Hypertension | 3 (4.2) | |
| Sickle cell disease | 2 (2.8) |
Descriptive Statistics for Clinical Characteristics of Participants
| Ultrasound Scan Findings | Findings | Frequency (%) |
|---|---|---|
| Infants | Absence of gallbladder | 7 (100) |
| Atretic extrahepatic duct | 6 (85.7) | |
| Ascites | 2 (28.6) | |
| Children and adults | Dilated bile ducts | 47 (66.2) |
| Distended gall bladder | 34 (47.9) | |
| Pancreatic mass | 28 (39.4) | |
| RUQ abdominal mass | 21 (29.6) | |
| Ascites | 20 (27.8) | |
| Stones in common bile duct | 15 (21.1) | |
| Stones in gallbladder | 11 (15.5) | |
| Level of obstruction | ||
| Lower third | 40 (55.6) | |
| Middle third | 22 (30.6) | |
| Upper third | 10 (13.9) | |
| Liver function tests | Value | Interquartile range (IQR) |
| Conjugated bilirubin (µmol/L) | 105.20 | (78.2–111.0) |
| Unconjugated bilirubin (µmol/L) | 20.4 | (6.8–23) |
| Total bilirubin (µmol/L) | 119.8 | (112.4–128) |
| Alkaline phosphatase (U/L) | 1194 | (1001–1327) |
| Gamma-glutamyl transferase (U/L) | 200 | (122–250) |
| Aspartate transaminase (U/L) | 36 | (23.0–46.0) |
| Alanine transaminase (U/L) | 33 | (21.0–43.0) |
| White cell counts (x109 cells /ul) | 6.4 | (5.2–10) |
| Red blood count (x109 cells /ul) | 3.4 | (2.9–4.4) |
| Hemoglobin (g/dL) | 11.9 | (10.7–13.0) |
| International normalized ratio | 1.2 | (1.1–1.3) |
| Prothrombin time (S) | 12 | (9.7–13.6) |
| Activated partial thromboplastin time (s) | 33 (30–35) |
Etiology of Extrahepatic Obstructive Jaundice
| Type | Aetiology | <1 yr | 1–14 Yrs | 15–35 Yrs | 36–50 Yrs | >50 Yrs | Total, N (%) |
|---|---|---|---|---|---|---|---|
| Benign | |||||||
| Male | 0 | 0 | 0 | 2 | 4 | 10 (13.9) | |
| Female | 0 | 0 | 0 | 2 | 2 | ||
| Male | 3 | 0 | 0 | 0 | 0 | 7 (9.7) | |
| Female | 4 | 0 | 0 | 0 | 0 | ||
| Male | 0 | 0 | 0 | 3 | 2 | 6 (8.3) | |
| Female | 0 | 1 | 0 | 0 | 0 | ||
| Male | 0 | 1 | 1 | 0 | 1 | 5 (6.9) | |
| Female | 0 | 0 | 1 | 1 | 0 | ||
| Male | 0 | 0 | 1 | 0 | 0 | 1 (1.4) | |
| Female | 0 | 0 | 0 | 0 | 0 | ||
| Male | 0 | 1 | 0 | 0 | 0 | 1 (1.4) | |
| Female | 0 | 0 | 0 | 0 | 0 | ||
| Total | 30 (41.7) | ||||||
| Malignant | |||||||
| Male | 0 | 0 | 0 | 1 | 10 | 20 (27.8) | |
| Female | 0 | 0 | 0 | 2 | 7 | ||
| Male | 0 | 0 | 0 | 2 | 6 | 13 (18.1) | |
| Female | 0 | 0 | 0 | 0 | 5 | ||
| Male | 0 | 0 | 0 | 1 | 2 | 5 (6.9) | |
| Female | 0 | 0 | 1 | 0 | 1 | ||
| Male | 0 | 0 | 0 | 0 | 1 | 4 (5.6) | |
| Female | 0 | 0 | 0 | 0 | 3 | ||
| Total | 42 (58.3) | ||||||
Clinical Presentations
| Clinical Manifestations | Benign n, (%) | Malignant n, (%) | Total n, (%) | P value |
|---|---|---|---|---|
| Yellow discoloration of eyes | 30 (41.6) | 42 (58.4) | 72 (100) | 0.226 |
| RUQ pain/tenderness | 25 (34.7) | 42 (58.4) | 67 (93.1) | 0.013 |
| Abdominal pain | 25 (34.7) | 40 (55.6) | 65 (90.3) | 0.179 |
| Dark urine | 21 (29.1) | 34 (47.2) | 55 (76.3) | 0.397 |
| Nausea and vomiting | 19 (26.3) | 31 (43.0) | 50 (69.3) | 0.452 |
| Loss of appetite | 10 (1.4) | 39 (54.1) | 49 (55.5) | <0.001 |
| Loss of weight | 15 (20.8) | 30 (41.6) | 45 (62.4) | 0.125 |
| Body itching | 13 (18.1) | 31 (43.1) | 44 (61.2) | 0.013 |
| Clay-colored stool | 12 (16.6) | 30 (41.6) | 42 (58.2) | 0.031 |
| Abdominal distension | 8 (11.1) | 33 (45.8) | 41 (56.9) | <0.001 |
| Scratch marks | 9 (12.5) | 31 (43.0) | 40 (55.5) | <0.001 |
| Abdominal mass | 10 (1.4) | 20 (27.7) | 37 (29.1) | 0.325 |
| Courvoisier’s sign | 0 (0) | 30 (41.6) | 30 (41.6) | <0.001 |
| Fever | 4 (5.5) | 6 (8.3) | 10 (13.8) | 0.099 |
| Confusion | 1 (1.3) | 5 (6.9) | 6 (8.2) | 0.208 |
| Hypotension | 1 (1.3) | 4 (5.5) | 5 (6.8) | 0.162 |
| Anemia | 0 (0) | 5 (6.9) | 5 (6.9) | 0.056 |
Figure 1Clinical characteristics of extrahepatic obstructive jaundice.
Figure 2Duration of symptoms at admission.
Figure 3Treatment modalities.
Surgical Procedures
| Procedures | Benign | Malignant | Total (%) |
|---|---|---|---|
| Cholecystectomy | 8 | 3 | 11 (25.6) |
| Cholecystojejunostomy + jejunojejunostomy | 0 | 8 | 8 (18.6) |
| Choledochoduodenostomy | 6 | 1 | 7 (16.3) |
| Roux-en-Y hepaticojejunostomy+ jejunojejunostomy | 1 | 3 | 4 (9.3) |
| Roux-en-Y cystojejunostomy | 3 | 0 | 3 (7.0) |
| Choledochotomy + cholecystectomy +T-Tube | 3 | 0 | 3 (7.0) |
| Cystogastrostomy | 2 | 0 | 2 (4.7) |
| Cholecystojejunostomy + gastrojejunostomy + jejunojejunostomy | 0 | 2 | 2 (4. 7) |
| Laparotomy +biopsy | 0 | 2 | 2 (4. 7) |
| Kasai portoenterostomy | 1 | 0 | 1 (2.3) |
| Total | 24 | 19 | 43 (100) |
Figure 4Mortality stratified by diagnosis and treatment modality.
Figure 5Mortality of extrahepatic obstructive jaundice.
Morbidities Associated with Extrahepatic Obstructive Jaundice
| Benign | Malignant | Total (%) | |||
|---|---|---|---|---|---|
| With Surgery | Without Surgery | With Surgery | Without Surgery | ||
| Anemia | 1 | 4 | 5 | 4 | 14 (26.4) |
| Ascending cholangitis | 1 | 5 | 3 | 9 (17.0) | |
| Wound dehiscence | 3 | 0 | 5 | 0 | 8 (15.1) |
| Hepatic encephalopathy | 0 | 0 | 0 | 5 | 5 (9.4) |
| Surgical site infection | 3 | 0 | 2 | 0 | 5 (9.4) |
| Coagulopathy | 0 | 1 | 0 | 2 | 3 (5.7) |
| Bile leak | 0 | 0 | 2 | 0 | 2 (3.8) |
| Deep vein thrombosis | 0 | 0 | 2 | 0 | 2 (3.8) |
| Cirrhosis/portal hypertension | 0 | 2 | 0 | 0 | 2 (3.8) |
| Failure to thrive | 0 | 2 | 0 | 0 | 2 (3.8) |
| Sepsis | 1 | 0 | 0 | 0 | 1 (1.9) |